Immunome Inc (NASDAQ:IMNM) has a beta value of 1.74 and has seen 1.18 million shares traded in the last trading session. The company, currently valued at $638.96M, closed the last trade at $9.82 per share which meant it gained $0.4 on the day or 4.25% during that session. The IMNM stock price is -215.27% off its 52-week high price of $30.96 and 29.43% above the 52-week low of $6.93. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.12 million shares traded. The 3-month trading volume is 695.20K shares.

The consensus among analysts is that Immunome Inc (IMNM) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.66.

Immunome Inc (NASDAQ:IMNM) trade information

Sporting 4.25% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the IMNM stock price touched $9.82 or saw a rise of 3.73%. Year-to-date, Immunome Inc shares have moved -8.22%, while the 5-day performance has seen it change -0.86%. Over the past 30 days, the shares of Immunome Inc (NASDAQ:IMNM) have changed -18.23%. Short interest in the company has seen 10.47 million shares shorted with days to cover at 18.28.

Wall Street analysts have a consensus price target for the stock at $33, which means that the shares’ value could jump 70.24% from current levels. The projected low price target is $23.0 while the price target rests at a high of $35.0. In that case, then, we find that the current price level is -256.42% off the targeted high while a plunge would see the stock gain -134.22% from current levels.

Immunome Inc (IMNM) estimates and forecasts

Figures show that Immunome Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -30.94% over the past 6 months, with this year growth rate of -242.75%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be -32.90%.

7 analysts offering their estimates for the company have set an average revenue estimate of 3.16M for the current quarter. Year-ago sales stood 3.83M and 1.03M respectively for this quarter and the next, and analysts expect sales will shrink by -17.51% for the current quarter and -32.90% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -48.48% over the past 5 years.

IMNM Dividends

Immunome Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Immunome Inc (NASDAQ:IMNM)’s Major holders

Insiders own 16.77% of the company shares, while shares held by institutions stand at 83.47% with a share float percentage of 100.30%. Investors are also buoyed by the number of investors in a company, with Immunome Inc having a total of 171.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 3.76 million shares worth more than $45.48 million. As of 2024-06-30, BLACKROCK INC. held 36.4624% of shares outstanding.

The other major institutional holder is REDMILE GROUP, LLC, with the holding of over 4.89 million shares as of 2024-06-30. The firm’s total holdings are worth over $59.16 million and represent 8.1579% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund . As of Jun 30, 2024 , the former fund manager holds about 2.62% shares in the company for having 1.64 shares of worth $16.07 million while later fund manager owns 1.5 shares of worth $14.78 million as of Jun 30, 2024 , which makes it owner of about 2.41% of company’s outstanding stock.